“GLP-1 Therapies Enter the CKM Guideline For the First Time, GLP-1-Based Therapy Is Recommended to Reduce Cardiac Events”. 2026. Diabzen 4 (18): 36-37. https://thediabzen.com/index.php/d/article/view/61.